GU Cancers 2022 | Genomic characterization of patients with de-novo high-volume mCSPC compared to those without

Nicolas Sayegh, MD, University of Utah, Salt Lake City, UT, presents findings from a retrospective investigation characterizing tumoral genomic features of patients with de-novo high-volume metastatic castration-sensitive prostate cancer compared to those without de-novo high-volume metastatic castration-sensitive prostate cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.